United Therapeutics (UTHR) Price & Analysis

Compare

612 Followers

UTHR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$266.98 - $417.82

Previous CloseN/A

Volume58.00K

Average Volume (3M)456.02K

Market Cap

$13.45B

Enterprise ValueN/A

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)11.9

Beta0.48

Next Earnings

Jul 30, 2025

EPS Estimate

7.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding45,106,625

10 Day Avg. Volume352,177

30 Day Avg. Volume456,018

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)0.00

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$383.00

Price Target Upside28.71% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering12

Bulls Say, Bears Say

Bulls Say

Commercial StrategyUTHR's established commercial footprint, longstanding relationships with key physicians/target prescribers, and proactive contracting efforts/favorable positioning with payers should help mitigate potential competitive pressures for the Tyvaso franchise.

Growth PotentialThere is still meaningful growth potential for the Tyvaso franchise in PH-ILD, which should continue to support the base business, with longer-term upside potential from IPF.

Therapeutic SynergyUTHR offers a whole solution of prostacyclin (IV, SC, nebulizer, DPI, oral) for PAH patients, creating therapeutic synergy when patients need to switch modalities.

Bears Say

CompetitionTotal Tyvaso franchise revenue forecasts have been trimmed by 4% to account for potentially greater competition.

Competitive PressuresMEDACorp KOLs seem to gravitate towards the convenience advantage of 1x-daily dosing potential of TPIP vs. UTHR's 4x daily approach with Tyvaso, which may drive patient switching in the PAH / PH-ILD space.

Potential RisksINSM's TPIP results reflect a key potential longer-term risk to UTHR's PAH franchise, and potentially PH-ILD as well.

United Therapeutics News

Notable companies reporting before tomorrow’s open

Notable companies reporting before tomorrow’s open, with earnings consensus, include Altria Group (MO), consensus $1.38… Hershey (HSY), consensus...

16h ago

HOG

Bleecker Street Research short United Therapeutics, long Liquidia

Funds managed by Bleecker Street are short United Therapeutics and long Liquidia. In a recently published report titled...

19h ago

LQDA

UTHR

Oppenheimer bullish on United Therapeutics, sees grand upside from TETON readout

Oppenheimer says the firm’s proprietary upside/downside scenario analysis of potential stock moves and Oppenheimer’s implied valuation for United...

16d ago

UTHR

United Therapeutics price target lowered to $328 from $348 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on United Therapeutics (UTHR) to $328 from $348 and keeps an...

20d ago

UTHR

United Therapeutics price target lowered to $330 from $350 at JPMorgan

JPMorgan analyst Jessica Fye lowered the firm’s price target on United Therapeutics (UTHR) to $330 from $350 and...

22d ago

UTHR

United Therapeutics price target lowered to $385 from $410 at UBS

UBS lowered the firm’s price target on United Therapeutics (UTHR) to $385 from $410 and keeps a Buy...

30d ago

UTHR

United Therapeutics’ Inhaled Treprostinil Study: A Potential Game-Changer for Pulmonary Fibrosis

United Therapeutics Corp. (($UTHR)) announced an update on their ongoing clinical study. United Therapeutics Corp. is conducting a...

2d ago

UTHR

United Therapeutics’ Promising IPF Treatment Study: A Market Game-Changer?

United Therapeutics Corp. (($UTHR)) announced an update on their ongoing clinical study. United Therapeutics Corp. is conducting an...

2d ago

UTHR

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for IPF Treatment

United Therapeutics Corp. (($UTHR)) announced an update on their ongoing clinical study. United Therapeutics Corp. is conducting a...

2d ago

UTHR

United Therapeutics Corp. (UTHR) Q2 Earnings Cheat Sheet

United Therapeutics Corp. (UTHR) is scheduled to report 2nd quarter earnings on 07/30/2025, before the market opens. Regarding...

2d ago

UTHR

Positive Outlook for United Therapeutics Driven by Tyvaso Growth and IPF Potential

In a report released yesterday, Roanna Ruiz from Leerink Partners maintained a Buy rating on United Therapeutics, with...

6d ago

UTHR

Optimistic Buy Rating for United Therapeutics Amid Promising Tyvaso Developments in IPF Treatment

Analyst Joseph Thome from TD Cowen maintained a Buy rating on United Therapeutics and keeping the price target...

15d ago

UTHR

United Therapeutics’ Phase 3 Study on Inhaled Treprostinil: A Potential Game-Changer for Pulmonary Fibrosis

United Therapeutics Corp. (($UTHR)) announced an update on their ongoing clinical study. United Therapeutics Corp. is conducting a...

19d ago

UTHR

United Therapeutics’ DeciPHer-ILD Study: A New Frontier in Pulmonary Hypertension Research

United Therapeutics Corp. (($UTHR)) announced an update on their ongoing clinical study. United Therapeutics Corp. is currently recruiting...

19d ago

UTHR

UTHR FAQ

What was United Therapeutics’s price range in the past 12 months?

United Therapeutics lowest stock price was $266.98 and its highest was $417.81 in the past 12 months.

What is United Therapeutics’s market cap?

United Therapeutics’s market cap is $13.45B.

When is United Therapeutics’s upcoming earnings report date?

United Therapeutics’s upcoming earnings report date is Jul 30, 2025 which is today.

How were United Therapeutics’s earnings last quarter?

Currently, no data Available

Is United Therapeutics overvalued?

According to Wall Street analysts United Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does United Therapeutics pay dividends?

United Therapeutics does not currently pay dividends.

What is United Therapeutics’s EPS estimate?

United Therapeutics’s EPS estimate is 7.27.

How many shares outstanding does United Therapeutics have?

United Therapeutics has 45,106,625 shares outstanding.

What happened to United Therapeutics’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of United Therapeutics?

Currently, no hedge funds are holding shares in UTHR

United Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

19.94%

Trailing 12-Months

Asset Growth

19.22%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company primarily operates in the pharmaceutical sector, specializing in the development of therapies for pulmonary arterial hypertension (PAH) and other conditions. Its core products include Remodulin, Tyvaso, Orenitram, and Unituxin, which are used to treat various forms of PAH and certain types of cancer.

United Therapeutics (UTHR) Earnings & Revenues

UTHR Earnings Data >

UTHR Company Deck

UTHR Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a positive outlook with record revenue growth and strategic investments in pipeline expansion and capital allocation. Despite facing challenges in xenotransplantation and an increasingly competitive landscape, the company remains confident in sustained double-digit growth and product portfolio strength.Read More>

UTHR Revenue Breakdown

53.01% Tyvaso

21.26% Remodulin

15.44% Orenitram

8.55% Unituxin

1.75% Other

UTHR Stock 12 Month Forecast

Average Price Target

$383.00

▲(28.71%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"$289","400":"$400","511":"$511","344.5":"$344.5","455.5":"$455.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":510,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$510.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":383,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$383.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":314,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$314.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,344.5,400,455.5,511],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.91,307.76307692307694,324.61615384615385,341.46923076923076,358.32230769230773,375.1753846153846,392.02846153846156,408.88153846153847,425.7346153846154,442.5876923076923,459.4407692307692,476.2938461538462,493.14692307692303,{"y":510,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.91,297.99384615384616,305.0776923076923,312.1615384615385,319.24538461538464,326.3292307692308,333.4130769230769,340.4969230769231,347.58076923076925,354.6646153846154,361.7484615384615,368.8323076923077,375.91615384615386,{"y":383,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,290.91,292.68615384615384,294.4623076923077,296.23846153846154,298.0146153846154,299.79076923076923,301.5669230769231,303.3430769230769,305.1192307692308,306.8953846153846,308.6715384615385,310.4476923076923,312.2238461538461,{"y":314,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":319.01,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":327.79,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":363.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":357.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":374.02,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":370.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.84,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":351.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":320.05,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":306.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":293.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":325.48,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.91,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >